Alkem Laboratories has reported results for the fourth quarter (Q4FY26) and year ended March 31, 2026.
The company has reported 21.62% fall in its net profit at Rs 217.06 crore for the fourth quarter ended March 31, 2026 as compared to Rs 276.94 crore for the same quarter in the previous year. However, total income of the company has increased by 14.26% at Rs 2,464.13 crore for Q4FY26 as compared to Rs 2,156.53 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 22.69% fall in its net profit at Rs 236.46 crore for the fourth quarter ended March 31, 2026 as compared to Rs 305.86 crore for the same quarter in the previous year. However, total income of the company increased by 15.61% at Rs 3,803.39 crore for Q4FY26 as compared to Rs 3,289.71 crore for the corresponding quarter previous year.
For the year ended March 31, 2026, the company has reported marginal rise in its net profit at Rs 2,282.09 crore as compared to Rs 2,280.89 crore for the previous year. The total income of the company has increased by 9.64% at Rs 10,219.08 crore for year under review as compared to Rs 9,320.50 crore for year ended March 31, 2025.
For the year ended March 31, 2026, on the consolidated basis, the company has reported 6.30% rise in its net profit at Rs 2,301.80 crore as compared to Rs 2,165.48 crore for the previous year. The total income of the company increased by 13.65% at Rs 15,295.62 crore for year under review as compared to Rs 13,458.26 crore for year ended March 31, 2025.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1938.85 |
| Dr. Reddys Labs. | 1269.80 |
| Cipla | 1441.70 |
| Zydus Lifesciences | 1159.85 |
| Lupin | 2502.90 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: